SGD Pharma's Business Performance Reaches New Record
In the first half of 2019, SGD Pharma’s operations were carried out in an orderly manner, and all operational indicators hit a record high. In the first half of the year, SGD Pharma achieved sales revenue of 170 million euros, an increase of 5.7% over the previous year, and further increased its global market share; EBITDA was 47.7 million euros, an increase of 30.3% over the previous year; net attribution profit was 18.5 million euros, an increase of 263% over the previous year. The China business also grew rapidly, contributing 40% to the total revenue growth.
In the first half of 2019, JIC Investment Co., Ltd. ("JIC Investment") vigorously promoted the research and formulation of strategic planning for SGD Pharma, studied deeply the relevant countermeasures of SGD Pharma in the Chinese market, strengthened strategic implementation, adjusted and optimized the organizational structure, enhanced market service capacity and response time, steadily improved SGD Pharma's business performance, and maintained SGD Pharma's global brand reputation.